Cargando…

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety

BACKGROUND AND OBJECTIVE: Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson’s disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa–carbidopa intestinal gel (LCIG) provides individualized continuous levodopa–carbidop...

Descripción completa

Detalles Bibliográficos
Autores principales: Othman, Ahmed A., Chatamra, Krai, Mohamed, Mohamed-Eslam F., Dutta, Sandeep, Benesh, Janet, Yanagawa, Masayoshi, Nagai, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559582/
https://www.ncbi.nlm.nih.gov/pubmed/25875940
http://dx.doi.org/10.1007/s40262-015-0265-3
_version_ 1782388798493032448
author Othman, Ahmed A.
Chatamra, Krai
Mohamed, Mohamed-Eslam F.
Dutta, Sandeep
Benesh, Janet
Yanagawa, Masayoshi
Nagai, Masahiro
author_facet Othman, Ahmed A.
Chatamra, Krai
Mohamed, Mohamed-Eslam F.
Dutta, Sandeep
Benesh, Janet
Yanagawa, Masayoshi
Nagai, Masahiro
author_sort Othman, Ahmed A.
collection PubMed
description BACKGROUND AND OBJECTIVE: Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson’s disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa–carbidopa intestinal gel (LCIG) provides individualized continuous levodopa–carbidopa delivery through intrajejunal infusion. This study evaluated the pharmacokinetics, safety, and efficacy of LCIG relative to LC-oral in Japanese subjects with advanced PD. METHODS: Subjects with advanced PD were converted from their anti-PD medications to individually optimized doses of LC-oral (10:1 levodopa:carbidopa ratio) for 28 days (baseline; period 1) followed by switching to intrajejunal infusion of LCIG (4:1 ratio) for 21 days (period 2). Pharmacokinetics, adverse events (AEs), and efficacy were assessed. RESULTS: Eight patients were enrolled. Six received LCIG and four reported at least one AE [most common: fall (33.3 %), dyskinesia (33.3 %)]; one discontinued due to an AE. The average daily dose was 1230/123 and 1370/342 mg levodopa/carbidopa for LC-oral and LCIG, respectively, at the end of each period. The degree of fluctuation and intra-subject variability of levodopa plasma concentrations were 5.5- and 4-fold lower, respectively, with LCIG than with LC-oral. Levodopa bioavailability was 99 % for LCIG relative to LC-oral. Compared with baseline, LCIG decreased “Off” time (2.68 h, P = 0.002) and increased “On” time without troublesome dyskinesia (2.35 h, P = 0.006) in the PD Diary(©). With the small sample size, no statistically significant changes were seen on other efficacy endpoints. CONCLUSIONS: In Japanese subjects with advanced PD, LCIG resulted in an improved pharmacokinetic profile that appeared to be associated with reduced motor complications compared with LC-oral. These results extend previous findings in mainly Caucasian populations.
format Online
Article
Text
id pubmed-4559582
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-45595822015-09-10 Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety Othman, Ahmed A. Chatamra, Krai Mohamed, Mohamed-Eslam F. Dutta, Sandeep Benesh, Janet Yanagawa, Masayoshi Nagai, Masahiro Clin Pharmacokinet Original Research Article BACKGROUND AND OBJECTIVE: Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson’s disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa–carbidopa intestinal gel (LCIG) provides individualized continuous levodopa–carbidopa delivery through intrajejunal infusion. This study evaluated the pharmacokinetics, safety, and efficacy of LCIG relative to LC-oral in Japanese subjects with advanced PD. METHODS: Subjects with advanced PD were converted from their anti-PD medications to individually optimized doses of LC-oral (10:1 levodopa:carbidopa ratio) for 28 days (baseline; period 1) followed by switching to intrajejunal infusion of LCIG (4:1 ratio) for 21 days (period 2). Pharmacokinetics, adverse events (AEs), and efficacy were assessed. RESULTS: Eight patients were enrolled. Six received LCIG and four reported at least one AE [most common: fall (33.3 %), dyskinesia (33.3 %)]; one discontinued due to an AE. The average daily dose was 1230/123 and 1370/342 mg levodopa/carbidopa for LC-oral and LCIG, respectively, at the end of each period. The degree of fluctuation and intra-subject variability of levodopa plasma concentrations were 5.5- and 4-fold lower, respectively, with LCIG than with LC-oral. Levodopa bioavailability was 99 % for LCIG relative to LC-oral. Compared with baseline, LCIG decreased “Off” time (2.68 h, P = 0.002) and increased “On” time without troublesome dyskinesia (2.35 h, P = 0.006) in the PD Diary(©). With the small sample size, no statistically significant changes were seen on other efficacy endpoints. CONCLUSIONS: In Japanese subjects with advanced PD, LCIG resulted in an improved pharmacokinetic profile that appeared to be associated with reduced motor complications compared with LC-oral. These results extend previous findings in mainly Caucasian populations. Springer International Publishing 2015-04-15 2015 /pmc/articles/PMC4559582/ /pubmed/25875940 http://dx.doi.org/10.1007/s40262-015-0265-3 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research Article
Othman, Ahmed A.
Chatamra, Krai
Mohamed, Mohamed-Eslam F.
Dutta, Sandeep
Benesh, Janet
Yanagawa, Masayoshi
Nagai, Masahiro
Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
title Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
title_full Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
title_fullStr Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
title_full_unstemmed Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
title_short Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
title_sort jejunal infusion of levodopa–carbidopa intestinal gel versus oral administration of levodopa–carbidopa tablets in japanese subjects with advanced parkinson’s disease: pharmacokinetics and pilot efficacy and safety
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559582/
https://www.ncbi.nlm.nih.gov/pubmed/25875940
http://dx.doi.org/10.1007/s40262-015-0265-3
work_keys_str_mv AT othmanahmeda jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety
AT chatamrakrai jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety
AT mohamedmohamedeslamf jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety
AT duttasandeep jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety
AT beneshjanet jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety
AT yanagawamasayoshi jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety
AT nagaimasahiro jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety